Lannett Receives FDA Approval for Diethylpropion HCl Extended Release Tablets, 75 mg
Lannett Company, Inc. (NYSE: LCI) today announced that it has received approval from the U.S. Food and Drug Administration of its Abbreviated New Drug Application for Diethylpropion HCl Extended Release Tablets, 75 mg. Sales of Diethylpropion HCl Extended Release Tablets, 75 mg, at Average Wholesale Price were approximately $7.6 million on an annual basis, according to Wolters Kluwer.
Diethylpropion HCl, as with most anti-obesity drugs, primarily is sold to bariatric clinics; as a result, prescriptions do not reflect the entire market. The company expects to commence shipping immediately.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.